PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone775-832-8500
Debt
Debt-to-Equity Ratio0.17
Current Ratio11.13
Quick Ratio10.80
Price-To-Earnings
Trailing P/E Ratio3.70
Forward P/E Ratio-3.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$320.06 million
Price / Sales1.06
Cash Flow$0.8792 per share
Price / Cash2.65
Book Value$5.48 per share
Price / Book0.43
Profitability
EPS (Most Recent Fiscal Year)$0.63
Net Income$110.74 million
Net Margins-31.33%
Return on Equity8.92%
Return on Assets6.37%
Miscellaneous
Employees87
Outstanding Shares145,400,000
Market Cap$338.78 million
PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions
What is PDL BioPharma's stock symbol?
PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."
How will PDL BioPharma's stock buyback program work?
PDL BioPharma declared that its Board of Directors has authorized a stock buyback plan on Monday, September 25th 2017, which authorizes the company to repurchase $25,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.
How were PDL BioPharma's earnings last quarter?
PDL BioPharma Inc (NASDAQ:PDLI) announced its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.04. The biotechnology company had revenue of $46.58 million for the quarter. PDL BioPharma had a negative net margin of 31.33% and a positive return on equity of 8.92%. View PDL BioPharma's Earnings History.
When is PDL BioPharma's next earnings date?
What price target have analysts set for PDLI?
1 Wall Street analysts have issued twelve-month target prices for PDL BioPharma's shares. Their predictions range from $2.50 to $2.50. On average, they anticipate PDL BioPharma's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price. View Analyst Price Targets for PDL BioPharma.
What is the consensus analysts' recommendation for PDL BioPharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.
Who are some of PDL BioPharma's key competitors?
Some companies that are related to PDL BioPharma include Acorda Therapeutics (ACOR), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Autolus Therapeutics (AUTL), Cellectis (CLLS), DBV TECHNOLOGIE/S (DBVT), Avrobio (AVRO), BAVARIAN NORDIC/S (BVNRY), Adaptimmune Therapeutics (ADAP), BioCryst Pharmaceuticals (BCRX), Heska (HSKA), CASI Pharmaceuticals (CASI), Voyager Therapeutics (VYGR), La Jolla Pharmaceutical (LJPC) and Fate Therapeutics (FATE).
Who are PDL BioPharma's key executives?
PDL BioPharma's management team includes the folowing people:
- Mr. John Peter McLaughlin, CEO & Director (Age 66)
- Mr. Dominique P. Monnet, Pres (Age 57)
- Mr. Peter S. Garcia, VP & CFO (Age 56)
- Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 54)
- Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.
Has PDL BioPharma been receiving favorable news coverage?
News coverage about PDLI stock has been trending positive on Tuesday, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PDL BioPharma earned a media and rumor sentiment score of 0.41 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 47.78 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for PDL BioPharma.
Who are PDL BioPharma's major shareholders?
PDL BioPharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.31%), Dimensional Fund Advisors LP (8.31%), Renaissance Technologies LLC (6.43%), Connor Clark & Lunn Investment Management Ltd. (3.77%), Acadian Asset Management LLC (2.66%) and Schwab Charles Investment Management Inc. (2.37%). View Institutional Ownership Trends for PDL BioPharma.
Which institutional investors are selling PDL BioPharma stock?
PDLI stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Acadian Asset Management LLC, SG Americas Securities LLC, BlackRock Inc., Brandes Investment Partners LP, Bank of Montreal Can, California Public Employees Retirement System and Macquarie Group Ltd.. View Insider Buying and Selling for PDL BioPharma.
Which institutional investors are buying PDL BioPharma stock?
PDLI stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Connor Clark & Lunn Investment Management Ltd., West Family Investments Inc., Alambic Investment Management L.P., Schwab Charles Investment Management Inc., Hartford Investment Management Co., Strs Ohio and First Republic Investment Management Inc.. View Insider Buying and Selling for PDL BioPharma.
How do I buy shares of PDL BioPharma?
Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PDL BioPharma's stock price today?
One share of PDLI stock can currently be purchased for approximately $2.33.
How big of a company is PDL BioPharma?
PDL BioPharma has a market capitalization of $338.78 million and generates $320.06 million in revenue each year. The biotechnology company earns $110.74 million in net income (profit) each year or $0.63 on an earnings per share basis. PDL BioPharma employs 87 workers across the globe.
How can I contact PDL BioPharma?
PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]
MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
